The stock of Radius Health Inc (NASDAQ:RDUS) is a huge mover today! About 468,876 shares traded hands. Radius Health Inc (NASDAQ:RDUS) has risen 11.41% since April 4, 2016 and is uptrending. It has outperformed by 10.32% the S&P500.
The move comes after 6 months positive chart setup for the $1.64 billion company. It was reported on Nov, 4 by Barchart.com. We have $49.15 PT which if reached, will make NASDAQ:RDUS worth $328.00 million more.
Radius Health Inc (NASDAQ:RDUS) Ratings Coverage
Out of 9 analysts covering Radius Health (NASDAQ:RDUS), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Radius Health has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. As per Monday, May 23, the company rating was initiated by H.C. Wainwright. The rating was initiated by Deutsche Bank with “Buy” on Friday, August 14. On Friday, October 2 the stock rating was initiated by JP Morgan with “Overweight”. Goldman Sachs initiated it with “Neutral” rating and $37 target price in Wednesday, March 30 report. The firm has “Hold” rating by Jefferies given on Wednesday, February 24. As per Friday, May 6, the company rating was reinitiated by Cowen & Co. The rating was maintained by H.C. Wainwright on Wednesday, September 21 with “Buy”. Canaccord Genuity maintained it with “Buy” rating and $85.0 target price in Thursday, September 24 report.
According to Zacks Investment Research, “Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.32 in 2016 Q2. Its up 0.03, from 1.29 in 2016Q1. The ratio improved, as 20 funds sold all Radius Health Inc shares owned while 33 reduced positions. 22 funds bought stakes while 48 increased positions. They now own 42.68 million shares or 5.94% more from 40.29 million shares in 2016Q1.
Next Grp Incorporated owns 150 shares or 0% of their US portfolio. Dekabank Deutsche Girozentrale has invested 0.01% of its portfolio in Radius Health Inc (NASDAQ:RDUS). Envestnet Asset Mngmt last reported 6,724 shares in the company. Metropolitan Life Ins Ny holds 0.01% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 23,097 shares. Nicholas Prtnrs Lp accumulated 0.16% or 60,935 shares. Moreover, Lord Abbett Ltd Com has 0.01% invested in Radius Health Inc (NASDAQ:RDUS) for 65,604 shares. Public Employees Retirement Association Of Colorado last reported 0% of its portfolio in the stock. Proshare Advsr Limited Liability holds 0.02% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 37,023 shares. Bnp Paribas Arbitrage accumulated 0% or 1,223 shares. Bank & Trust Of Montreal Can holds 0% or 497 shares in its portfolio. Carl Domino Inc last reported 5,500 shares in the company. Macquarie Gru Limited, a Australia-based fund reported 20,320 shares. Pictet Asset Mgmt Ltd, a United Kingdom-based fund reported 216,060 shares. Citigroup holds 0.01% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 164,190 shares. Creative Planning accumulated 2,600 shares or 0% of the stock.
RDUS Company Profile
Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. The Company’s preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.